|
1
|
Senan S, Cardenal F, Vansteenkiste J,
Stigt J, Akyol F, De Neve W, Bakker J, Dupont JM, Scagliotti GV,
Ricardi U and van Meerbeeck JP: A randomized phase II study
comparing induction or consolidation chemotherapy with
cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with
cisplatin-docetaxel, in patients with unresectable locally advanced
non-small-cell lung cancer. Ann Oncol. 22:553–558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sekine I, Nokihara H, Takeda K, Nishiwaki
Y, Nakagawa K, Isobe H, Mori K, Matsui K, Saijo N and Tamura T:
Randomised phase II trial of irinotecan plus cisplatin vs
irinotecan, cisplatin plus etoposide repeated every 3 weeks in
patients with extensive-disease small-cell lung cancer. Br J
Cancer. 98:693–696. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tai CJ, Wang CK, Tai CJ, Tzao C, Lien YC,
Hsieh CC, Hsieh CI, Wu HC, Wu CH, Chang CC, et al: Evaluation of
safety and efficacy of salvage therapy with sunitinib, docetaxel
(Tyxane) and cisplatinum followed by maintenance vinorelbine for
unresectable/metastatic nonsmall cell lung cancer: Stage 1 of a
simon 2 stage clinical trial. Medicine (Baltimore). 94:e23032015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang CP, Wu BH, Chen SP, Fu MY, Yang M,
Liu F and Wang BQ: High COL4A3 expression correlates with poor
prognosis after cisplatin plus gemcitabine chemotherapy in
non-small cell lung cancer. Tumour Biol. 34:415–420. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang R, Ma L, Weng D, Yao J, Liu X and Jin
F: Gallic acid induces apoptosis and enhances the anticancer
effects of cisplatin in human small cell lung cancer H446 cell line
via the ROS-dependent mitochondrial apoptotic pathway. Oncol Rep.
35:3075–3083. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou W, Tian D, He J, Wang Y, Zhang L, Cui
L, Jia L, Zhang L, Li L, Shu Y, et al: Repeated PM2.5 exposure
inhibits BEAS-2B cell P53 expression through ROS-Akt-DNMT3B
pathway-mediated promoter hypermethylation. Oncotarget.
7:20691–20703. 2016.PubMed/NCBI
|
|
7
|
Matsumoto M, Nakajima W, Seike M, Gemma A
and Tanaka N: Cisplatin-induced apoptosis in non-small-cell lung
cancer cells is dependent on Bax- and Bak-induction pathway and
synergistically activated by BH3-mimetic ABT-263 in p53 wild-type
and mutant cells. Biochem Biophys Res Commun. 473:490–496. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou L, Jiang L, Xu M, Liu Q, Gao N, Li P
and Liu EH: Miltirone exhibits antileukemic activity by
ROS-mediated endoplasmic reticulum stress and mitochondrial
dysfunction pathways. Sci Rep. 6:205852016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mostallino MC, Mascia MP, Pisu MG,
Busonero F, Talani G and Biggio G: Inhibition by miltirone of
up-regulation of GABAA receptor alpha4 subunit mRNA by ethanol
withdrawal in hippocampal neurons. Eur J Pharmacol. 494:83–90.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou X, Wang Y, Hu T, Or PM, Wong J, Kwan
YW, Wan DC, Hoi PM, Lai PB and Yeung JH: Enzyme kinetic and
molecular docking studies for the inhibitions of miltirone on major
human cytochrome P450 isozymes. Phytomedicine. 20:367–374. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Hu T, Shen J, Zhang L, Li LF, Chan
RL, Li MX, Wu WK and Cho CH: Miltirone induced mitochondrial
dysfunction and ROS-dependent apoptosis in colon cancer cells. Life
Sci. 151:224–234. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Watanabe S, Inoue A, Nukiwa T and
Kobayashi K: Comparison of Gefitinib Versus Chemotherapy in
Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
Anticancer Res. 35:6957–6961. 2015.PubMed/NCBI
|
|
13
|
Shukuya T, Yamanaka T, Seto T, Daga H,
Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, et al:
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for
advanced or relapsed squamous cell carcinoma of the lung
(WJOG5208L): A randomised, open-label, phase 3 trial. Lancet Oncol.
16:1630–1638. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsunoda T, Koizumi T, Hayasaka M, Hirai K,
Koyama S, Takabayashi Y, Fujimoto K and Kubo K: Phase II study of
weekly docetaxel combined with cisplatin in patients with advanced
non-small-cell lung cancer. Cancer Chemother Pharmacol. 54:173–177.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tiseo M, Boni L, Ambrosio F, Camerini A,
Vitale MG, Baldini E, Cinieri S, Zanelli F, Defraia E, Passalacqua
R, et al: Italian multicenter phase III randomized study of
cisplatin-etoposide with or without bevacizumab as first-line
treatment in extensive stage small cell lung cancer: Treatment
rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.
Clin Lung Cancer. 16:67–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yun HS, Baek JH, Yim JH, Lee SJ, Lee CW,
Song JY, Um HD, Park JK, Park IC and Hwang SG: Knockdown of
hepatoma-derived growth factor-related protein-3 induces apoptosis
of H1299 cells via ROS-dependent and p53-independent NF-κB
activation. Biochem Biophys Res Commun. 449:471–476. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He L, Lai H and Chen T: Dual-function
nanosystem for synergetic cancer chemo-/radiotherapy through
ROS-mediated signaling pathways. Biomaterials. 51:30–42. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hong Y, Sengupta S, Hur W and Sim T:
Identification of Novel ROS Inducers: Quinone derivatives tethered
to long hydrocarbon Chains. J Med Chem. 58:3739–3750. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu Z, Zeng Q, Zhang B, Liu H and Wang W:
Promotion of p53 expression and reactive oxidative stress
production is involved in zerumbone-induced cisplatin sensitization
of non-small cell lung cancer cells. Biochimie. 107:Pt B. 257–262.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meijer A, Kruyt FA, van der Zee AG,
Hollema H, Le P, ten Hoor KA, Groothuis GM, Quax WJ, de Vries EG
and de Jong S: Nutlin-3 preferentially sensitises wild-type
p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br
J Cancer. 109:2685–2695. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hunter TB, Manimala NJ, Luddy KA, Catlin T
and Antonia SJ: Paclitaxel and TRAIL synergize to kill
paclitaxel-resistant small cell lung cancer cells through a
caspase-independent mechanism mediated through AIF. Anticancer Res.
31:3193–3204. 2011.PubMed/NCBI
|
|
22
|
Zhang W, Wang X and Chen T: Resveratrol
induces mitochondria-mediated AIF and to a lesser extent
caspase-9-dependent apoptosis in human lung adenocarcinoma ASTC-a-1
cells. Mol Cell Biochem. 354:29–37. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen JT, Huang CY, Chiang YY, Chen WH,
Chiou SH, Chen CY and Chow KC: HGF increases cisplatin resistance
via down-regulation of AIF in lung cancer cells. Am J Respir Cell
Mol Biol. 38:559–565. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cardnell RJ, Feng Y, Mukherjee S, Diao L,
Tong P, Stewart CA, Masrorpour F, Fan Y, Nilsson M, Shen Y, et al:
Activation of the PI3K/mTOR pathway following PARP inhibition in
small cell lung cancer. PLoS One. 11:e01525842016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tangutoori S, Baldwin P and Sridhar S:
PARP inhibitors: A new era of targeted therapy. Maturitas. 81:5–9.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gangopadhyay NN, Luketich JD, Opest A,
Landreneau R and Schuchert MJ: PARP inhibitor activates the
intrinsic pathway of apoptosis in primary lung cancer cells. Cancer
Invest. 32:339–348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cardnell RJ and Byers LA: Proteomic
markers of DNA repair and PI3K pathway activation predict response
to the PARP inhibitor BMN 673 in small cell lung cancer - response.
Clin Cancer Res. 20:22372014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu CF and Efferth T: Miltirone induces
G2/M cell cycle arrest and apoptosis in CCRF-CEM acute
lymphoblastic leukemia cells. J Nat Prod. 78:1339–1347. 2015.
View Article : Google Scholar : PubMed/NCBI
|
